[August 13, 2014] |
 |
Florida Institute and Dawson James Securities Complete Integene International Holdings Financing
GAINESVILLE & BOCA RATON, Fla. --(Business Wire)--
The Florida Institute
for the Commercialization of Public Research (Florida Institute)
announced today that it has finalized a funding agreement with Integene
International Holdings (Integene), a vascular biotechnology company
that has developed platform technology for ischemia and associated
complications. The Institute supports new company creation based on
publicly-funded research across the state, and bridges early funding
gaps for companies spinning out of universities and research
institutions. In order to qualify for Florida Institute funding,
companies must raise matching private investment capital.
In December 2013, the Florida Institute and Dawson James Securities,
Inc. ("Dawson James", Member FINRA/SPIC) announced an alliance to
augment early investment in emerging growth innovation companies.
Companies undergo a thorough review and vetting process led by the
Florida Institute, who provides up to $300,000 in funding to qualified
companies. Through the partnership, Dawson James leverages its vast
retail investor network to provide the required matching investment. In
this case, Dawson James was able to raise more funding than what was
required to match Florida Institute funds.
Integene was founded to capitalize on patented biotechnology created to
optimize gene and stem cell treatments for cardiovascular disease. The
company's founder, Dr. Keith Webster and his team, in association with
the University o Miami, have developed procedures for targeting and
regulating human growth factor genes within host tissues, and
bio-engineering stem cells to provide optimized therapies for ischemia
related disease.
According to Dr. Webster, "The fundraising support provided by Dawson
James enabled us to rapidly and efficiently raise the required matching
funds to qualify for funds provided by the Florida Institute. These
funds will be used to advance the clinical testing of treatments for
major life-threatening diseases, initially a condition known as critical
limb ischemia for which limb amputation may be the only option for many
patients and eventually multiple other cardiovascular indications,
diabetic retinopathy and solid tumors."
"Dawson James Securities has been assisting emerging growth companies
since 2004, and is interested in identifying and supporting quality new
companies spinning out of Florida's research institutions," said Robert
Keyser, Jr., Dawson James CEO. "As a full-service boutique investment
bank, we are pleased to leverage our broad investor placement
capabilities to support the growth of promising Florida companies."
"We formed this alliance to coordinate company financing from angel
investors, venture capitalists, private equity and public markets and to
expand Florida's innovation platform and investor base," said Jamie
Grooms, CEO of the Institute. "The Integene financing represents the
first transaction resulting from this alliance, and we will continue to
work with Dawson James to support the next generation of great Florida
companies."
About the Florida
Institute
Formed by the Florida Legislature in 2007, the Florida Institute for the
Commercialization of Public Research is a non-profit organization that
works collaboratively with the technology licensing and
commercialization offices of Florida's state universities and private
research institutions to leverage a $2B+ research base and form
investable companies that create clean jobs in new industries that are
driving the global economy. Over 100 new company projects have been
identified across the state, and the Institute deploys company building
and funding programs to promising Florida startups. Thirty-two companies
have been funded since the program's inception.
About Dawson
James Securities
Dawson James Securities, Inc., a member of FINRA/SPIC, is a full service
investment bank headquartered in Boca Raton, FL. Individuals with
interest in investment in emerging growth companies can contact an
appropriate Dawson James representative at 561-391-5555.
About Integene
International Holdings
Integene International Holdings is a biotech company that has developed
a comprehensive treatment for cardiovascular ischemic disease using
combinations of proprietary gene and stem cell procedures. Integene
technology is based on more than 20 years of NIH-supported pre-clinical
development and is currently initiating Phase I/II clinical trials for
the treatment of peripheral artery disease (PAD) using these procedures.

[ Back To TMCnet.com's Homepage ]
|